Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Troponin T | 11 | 2021 | 754 | 3.050 |
Why?
|
Cardiovascular Diseases | 51 | 2024 | 15165 | 2.530 |
Why?
|
Natriuretic Peptide, Brain | 10 | 2020 | 1573 | 2.470 |
Why?
|
Interleukin-1beta | 12 | 2020 | 972 | 1.810 |
Why?
|
Diabetes Mellitus, Type 2 | 34 | 2024 | 11725 | 1.640 |
Why?
|
Anti-Inflammatory Agents | 8 | 2020 | 1790 | 1.570 |
Why?
|
C-Reactive Protein | 19 | 2022 | 3778 | 1.400 |
Why?
|
Fluorobenzenes | 5 | 2015 | 183 | 1.390 |
Why?
|
Peptide Fragments | 7 | 2020 | 5097 | 1.250 |
Why?
|
Troponin I | 4 | 2020 | 619 | 1.140 |
Why?
|
Atherosclerosis | 11 | 2024 | 3445 | 1.120 |
Why?
|
Antibodies, Monoclonal | 11 | 2018 | 9274 | 0.890 |
Why?
|
Cholesterol, LDL | 9 | 2022 | 2356 | 0.880 |
Why?
|
Lupus Erythematosus, Systemic | 9 | 2021 | 2104 | 0.870 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2022 | 3255 | 0.850 |
Why?
|
Myocardium | 4 | 2020 | 4776 | 0.820 |
Why?
|
Sulfonamides | 5 | 2015 | 1938 | 0.810 |
Why?
|
Heart Failure | 13 | 2024 | 10900 | 0.800 |
Why?
|
Myocardial Ischemia | 3 | 2016 | 2148 | 0.760 |
Why?
|
Hypoglycemic Agents | 13 | 2024 | 2872 | 0.750 |
Why?
|
Cholesterol, HDL | 7 | 2022 | 1814 | 0.740 |
Why?
|
Colchicine | 1 | 2020 | 243 | 0.690 |
Why?
|
Pyrimidines | 5 | 2015 | 2942 | 0.680 |
Why?
|
Peripheral Arterial Disease | 3 | 2019 | 1188 | 0.660 |
Why?
|
Glucosides | 3 | 2024 | 451 | 0.650 |
Why?
|
Heart Injuries | 1 | 2020 | 210 | 0.640 |
Why?
|
Stroke | 18 | 2024 | 9981 | 0.640 |
Why?
|
Therapies, Investigational | 1 | 2019 | 112 | 0.630 |
Why?
|
Prediabetic State | 2 | 2021 | 499 | 0.630 |
Why?
|
Risk Factors | 47 | 2024 | 72290 | 0.620 |
Why?
|
Myocardial Infarction | 17 | 2024 | 11727 | 0.620 |
Why?
|
Cardiovascular Abnormalities | 1 | 2018 | 144 | 0.590 |
Why?
|
Vasculitis | 1 | 2020 | 519 | 0.550 |
Why?
|
Benzhydryl Compounds | 3 | 2024 | 845 | 0.550 |
Why?
|
Drug Approval | 3 | 2019 | 742 | 0.550 |
Why?
|
Medicaid | 7 | 2020 | 2736 | 0.530 |
Why?
|
Double-Blind Method | 18 | 2023 | 12026 | 0.520 |
Why?
|
Troponin | 2 | 2016 | 524 | 0.520 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2016 | 96 | 0.510 |
Why?
|
Metformin | 3 | 2017 | 835 | 0.510 |
Why?
|
Risk Assessment | 16 | 2021 | 23338 | 0.510 |
Why?
|
Thrombosis | 4 | 2021 | 2968 | 0.510 |
Why?
|
Proprotein Convertases | 1 | 2015 | 95 | 0.500 |
Why?
|
Vitamin E | 3 | 2015 | 869 | 0.500 |
Why?
|
Methotrexate | 3 | 2020 | 1727 | 0.490 |
Why?
|
Inflammasomes | 1 | 2019 | 495 | 0.480 |
Why?
|
Women's Health | 3 | 2015 | 2034 | 0.470 |
Why?
|
Heparin | 5 | 2021 | 1637 | 0.460 |
Why?
|
Hematuria | 1 | 2014 | 235 | 0.450 |
Why?
|
Atrial Fibrillation | 8 | 2022 | 5034 | 0.440 |
Why?
|
Coronary Disease | 4 | 2015 | 6077 | 0.430 |
Why?
|
Incidence | 23 | 2020 | 20947 | 0.430 |
Why?
|
Middle Aged | 72 | 2024 | 213383 | 0.430 |
Why?
|
Lipids | 6 | 2019 | 3305 | 0.420 |
Why?
|
Blood Glucose | 5 | 2019 | 6256 | 0.410 |
Why?
|
Death, Sudden, Cardiac | 1 | 2020 | 1541 | 0.410 |
Why?
|
Diabetes Mellitus | 3 | 2019 | 5751 | 0.410 |
Why?
|
Humans | 117 | 2024 | 744343 | 0.410 |
Why?
|
Death | 1 | 2016 | 678 | 0.400 |
Why?
|
Dyslipidemias | 1 | 2019 | 849 | 0.400 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 4 | 2022 | 293 | 0.390 |
Why?
|
Patient Admission | 1 | 2019 | 1380 | 0.390 |
Why?
|
Hydrochlorothiazide | 2 | 2008 | 98 | 0.390 |
Why?
|
Sulfonylurea Compounds | 3 | 2024 | 204 | 0.390 |
Why?
|
Aspirin | 4 | 2021 | 3282 | 0.380 |
Why?
|
Motor Activity | 2 | 2011 | 2714 | 0.380 |
Why?
|
Lipoprotein Lipase | 1 | 2011 | 126 | 0.370 |
Why?
|
Hypercholesterolemia | 2 | 2015 | 1151 | 0.370 |
Why?
|
Platelet Factor 4 | 3 | 2007 | 129 | 0.370 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2011 | 110 | 0.360 |
Why?
|
Aged | 50 | 2024 | 163280 | 0.360 |
Why?
|
Female | 81 | 2023 | 380194 | 0.350 |
Why?
|
Diabetes Complications | 2 | 2020 | 1359 | 0.350 |
Why?
|
Valine | 2 | 2008 | 413 | 0.350 |
Why?
|
Ambulatory Care | 2 | 2021 | 2708 | 0.340 |
Why?
|
Lipase | 1 | 2011 | 314 | 0.330 |
Why?
|
Anticholesteremic Agents | 1 | 2015 | 979 | 0.310 |
Why?
|
Clinical Trials as Topic | 4 | 2019 | 7913 | 0.310 |
Why?
|
Prospective Studies | 24 | 2023 | 53288 | 0.310 |
Why?
|
Q Fever | 1 | 2007 | 37 | 0.300 |
Why?
|
Disease Management | 1 | 2018 | 2459 | 0.290 |
Why?
|
Interleukin-18 | 1 | 2008 | 249 | 0.280 |
Why?
|
Estrogen Replacement Therapy | 3 | 2011 | 1203 | 0.280 |
Why?
|
Male | 62 | 2023 | 350118 | 0.270 |
Why?
|
Liver Diseases | 1 | 2014 | 1253 | 0.270 |
Why?
|
Sex Characteristics | 1 | 2016 | 2585 | 0.270 |
Why?
|
Extracellular Matrix Proteins | 1 | 2010 | 849 | 0.270 |
Why?
|
Anticoagulants | 6 | 2023 | 4599 | 0.270 |
Why?
|
Tetrazoles | 2 | 2008 | 835 | 0.260 |
Why?
|
Fibrinogen | 3 | 2016 | 894 | 0.260 |
Why?
|
Follow-Up Studies | 19 | 2020 | 39050 | 0.260 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2014 | 1004 | 0.260 |
Why?
|
Toll-Like Receptor 2 | 1 | 2007 | 354 | 0.260 |
Why?
|
Calcium-Binding Proteins | 1 | 2010 | 1081 | 0.260 |
Why?
|
Blood Proteins | 1 | 2010 | 1124 | 0.250 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2014 | 15519 | 0.250 |
Why?
|
Inflammation | 6 | 2020 | 10638 | 0.250 |
Why?
|
Diuretics | 1 | 2008 | 592 | 0.250 |
Why?
|
Intercellular Adhesion Molecule-1 | 4 | 2016 | 1155 | 0.250 |
Why?
|
Thromboembolism | 2 | 2010 | 986 | 0.240 |
Why?
|
Heart | 1 | 2017 | 4467 | 0.240 |
Why?
|
Fibroblast Growth Factors | 1 | 2010 | 879 | 0.240 |
Why?
|
Toll-Like Receptor 4 | 1 | 2007 | 565 | 0.240 |
Why?
|
Inflammation Mediators | 3 | 2019 | 1889 | 0.240 |
Why?
|
Gout | 2 | 2022 | 573 | 0.240 |
Why?
|
Venous Thromboembolism | 2 | 2023 | 1671 | 0.230 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2021 | 10943 | 0.220 |
Why?
|
Cohort Studies | 18 | 2023 | 40561 | 0.220 |
Why?
|
Risk | 7 | 2020 | 9687 | 0.220 |
Why?
|
Drug Therapy, Combination | 6 | 2017 | 6489 | 0.210 |
Why?
|
Proportional Hazards Models | 13 | 2021 | 12354 | 0.210 |
Why?
|
Antibodies | 3 | 2007 | 2460 | 0.210 |
Why?
|
Glucose Metabolism Disorders | 1 | 2021 | 54 | 0.200 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2021 | 3068 | 0.200 |
Why?
|
Antihypertensive Agents | 2 | 2008 | 2046 | 0.200 |
Why?
|
PPAR alpha | 1 | 2022 | 197 | 0.190 |
Why?
|
Angina, Unstable | 2 | 2016 | 926 | 0.190 |
Why?
|
Mass Screening | 1 | 2016 | 5255 | 0.190 |
Why?
|
Hypertension | 6 | 2016 | 8480 | 0.190 |
Why?
|
Natriuretic Peptides | 1 | 2021 | 150 | 0.190 |
Why?
|
Interleukin-6 | 5 | 2018 | 3200 | 0.190 |
Why?
|
Primary Ovarian Insufficiency | 1 | 2021 | 115 | 0.180 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2018 | 9959 | 0.180 |
Why?
|
Lipoprotein(a) | 2 | 2014 | 435 | 0.180 |
Why?
|
Life Style | 2 | 2024 | 3835 | 0.180 |
Why?
|
Treatment Outcome | 14 | 2023 | 63114 | 0.180 |
Why?
|
Azathioprine | 1 | 2021 | 353 | 0.180 |
Why?
|
Secondary Prevention | 3 | 2021 | 1530 | 0.170 |
Why?
|
Hypertriglyceridemia | 1 | 2022 | 293 | 0.170 |
Why?
|
Mycophenolic Acid | 1 | 2021 | 343 | 0.170 |
Why?
|
Antioxidants | 2 | 2019 | 1663 | 0.170 |
Why?
|
Current Procedural Terminology | 1 | 2019 | 92 | 0.170 |
Why?
|
Brain Ischemia | 3 | 2011 | 3265 | 0.170 |
Why?
|
Predictive Value of Tests | 7 | 2019 | 15076 | 0.170 |
Why?
|
Blood Pressure | 3 | 2011 | 8554 | 0.170 |
Why?
|
Apolipoprotein A-I | 2 | 2011 | 281 | 0.160 |
Why?
|
United States | 19 | 2024 | 69872 | 0.160 |
Why?
|
Hemorrhage | 4 | 2023 | 3461 | 0.160 |
Why?
|
Diet | 1 | 2016 | 7939 | 0.160 |
Why?
|
Hypolipidemic Agents | 1 | 2022 | 604 | 0.160 |
Why?
|
Benzoxazoles | 1 | 2018 | 77 | 0.160 |
Why?
|
Butyrates | 1 | 2018 | 163 | 0.150 |
Why?
|
Expert Testimony | 1 | 2020 | 356 | 0.150 |
Why?
|
Opportunistic Infections | 1 | 2021 | 389 | 0.150 |
Why?
|
Vaccination | 2 | 2021 | 3278 | 0.150 |
Why?
|
Research Report | 1 | 2020 | 355 | 0.150 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4149 | 0.150 |
Why?
|
Pyridones | 1 | 2021 | 712 | 0.140 |
Why?
|
Polymorphism, Genetic | 1 | 2007 | 4328 | 0.140 |
Why?
|
Thrombocytopenia | 4 | 2017 | 1179 | 0.140 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2022 | 2208 | 0.140 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 255 | 0.140 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2242 | 0.130 |
Why?
|
Clone Cells | 1 | 2019 | 1692 | 0.130 |
Why?
|
Incretins | 1 | 2016 | 88 | 0.130 |
Why?
|
Coronary Artery Disease | 4 | 2018 | 6487 | 0.130 |
Why?
|
Cardiovascular System | 2 | 2020 | 832 | 0.130 |
Why?
|
Myocardial Revascularization | 2 | 2016 | 841 | 0.130 |
Why?
|
Adult | 24 | 2024 | 214055 | 0.130 |
Why?
|
Algorithms | 4 | 2019 | 13881 | 0.120 |
Why?
|
Rheumatology | 1 | 2021 | 576 | 0.120 |
Why?
|
Triglycerides | 2 | 2022 | 2454 | 0.120 |
Why?
|
Consensus | 2 | 2021 | 2959 | 0.120 |
Why?
|
Coronary Artery Bypass | 3 | 2021 | 2289 | 0.120 |
Why?
|
International Classification of Diseases | 1 | 2019 | 867 | 0.120 |
Why?
|
Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
Hospitalization | 7 | 2023 | 10262 | 0.120 |
Why?
|
Placebos | 3 | 2020 | 1676 | 0.120 |
Why?
|
Cholesterol | 4 | 2022 | 2917 | 0.120 |
Why?
|
Infertility | 1 | 2021 | 655 | 0.120 |
Why?
|
Glucose | 5 | 2024 | 4397 | 0.110 |
Why?
|
Medicare | 5 | 2024 | 6566 | 0.110 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2014 | 374 | 0.110 |
Why?
|
Uric Acid | 1 | 2018 | 766 | 0.110 |
Why?
|
Sodium | 3 | 2022 | 1623 | 0.110 |
Why?
|
Smoking | 5 | 2017 | 8987 | 0.110 |
Why?
|
Propensity Score | 4 | 2021 | 1781 | 0.100 |
Why?
|
Case-Control Studies | 5 | 2020 | 21746 | 0.100 |
Why?
|
Health Promotion | 1 | 2024 | 2205 | 0.100 |
Why?
|
Cardiac Surgical Procedures | 1 | 2007 | 3537 | 0.100 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 393 | 0.100 |
Why?
|
Severity of Illness Index | 4 | 2020 | 15540 | 0.100 |
Why?
|
Advisory Committees | 1 | 2015 | 775 | 0.100 |
Why?
|
Hypoglycemia | 1 | 2018 | 861 | 0.100 |
Why?
|
Pyrazoles | 1 | 2021 | 1972 | 0.100 |
Why?
|
Health Literacy | 1 | 2016 | 414 | 0.100 |
Why?
|
Self Care | 1 | 2016 | 786 | 0.100 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2014 | 290 | 0.090 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1339 | 0.090 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 1072 | 0.090 |
Why?
|
Prognosis | 5 | 2019 | 29063 | 0.090 |
Why?
|
Hyperlipidemias | 2 | 2022 | 789 | 0.090 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 522 | 0.090 |
Why?
|
Genetic Markers | 2 | 2014 | 2634 | 0.090 |
Why?
|
Vitamins | 2 | 2015 | 1622 | 0.090 |
Why?
|
Hematopoiesis | 1 | 2019 | 2072 | 0.090 |
Why?
|
Cardiology | 1 | 2020 | 1668 | 0.080 |
Why?
|
Leisure Activities | 1 | 2011 | 311 | 0.080 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2010 | 153 | 0.080 |
Why?
|
Endocarditis | 2 | 2010 | 350 | 0.080 |
Why?
|
Foot Diseases | 1 | 2010 | 143 | 0.080 |
Why?
|
Comorbidity | 4 | 2018 | 10388 | 0.080 |
Why?
|
Postoperative Period | 2 | 2018 | 1842 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 4 | 2014 | 17446 | 0.080 |
Why?
|
Population Surveillance | 1 | 2019 | 2616 | 0.080 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 1584 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2727 | 0.080 |
Why?
|
Primary Prevention | 1 | 2015 | 1167 | 0.080 |
Why?
|
Health Expenditures | 1 | 2020 | 2348 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4217 | 0.070 |
Why?
|
Plant Extracts | 1 | 2010 | 471 | 0.070 |
Why?
|
Odds Ratio | 2 | 2021 | 9849 | 0.070 |
Why?
|
Young Adult | 8 | 2021 | 56430 | 0.070 |
Why?
|
Embolism | 1 | 2009 | 408 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1577 | 0.070 |
Why?
|
Cause of Death | 4 | 2021 | 3584 | 0.070 |
Why?
|
Adolescent | 8 | 2024 | 85781 | 0.070 |
Why?
|
Caffeine | 1 | 2010 | 699 | 0.070 |
Why?
|
Aging, Premature | 1 | 2005 | 47 | 0.070 |
Why?
|
Time Factors | 5 | 2019 | 40075 | 0.060 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 707 | 0.060 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 451 | 0.060 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2021 | 339 | 0.060 |
Why?
|
Lamin Type A | 1 | 2005 | 190 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 6538 | 0.060 |
Why?
|
Body Mass Index | 2 | 2013 | 12720 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1889 | 0.060 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 3870 | 0.060 |
Why?
|
Retrospective Studies | 6 | 2022 | 77449 | 0.060 |
Why?
|
Mortality | 3 | 2021 | 2864 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2018 | 3712 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8663 | 0.050 |
Why?
|
Heart Failure, Diastolic | 1 | 2023 | 69 | 0.050 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2022 | 88 | 0.050 |
Why?
|
Disease Progression | 1 | 2019 | 13284 | 0.050 |
Why?
|
Neutropenia | 2 | 2017 | 895 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2010 | 6364 | 0.050 |
Why?
|
Pancreatic Neoplasms | 2 | 2010 | 5256 | 0.050 |
Why?
|
Body Weight | 1 | 2013 | 4669 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 68 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 3923 | 0.050 |
Why?
|
Age Factors | 3 | 2016 | 18370 | 0.050 |
Why?
|
Immunity | 1 | 2007 | 1012 | 0.050 |
Why?
|
Apolipoprotein C-III | 1 | 2022 | 202 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10397 | 0.050 |
Why?
|
Matched-Pair Analysis | 1 | 2021 | 288 | 0.050 |
Why?
|
Committee Membership | 1 | 2020 | 15 | 0.050 |
Why?
|
Electrocardiography | 2 | 2011 | 6442 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2013 | 3966 | 0.050 |
Why?
|
Multi-Institutional Systems | 1 | 2019 | 43 | 0.040 |
Why?
|
Self Report | 1 | 2011 | 3558 | 0.040 |
Why?
|
Quality of Life | 1 | 2021 | 12804 | 0.040 |
Why?
|
Pleurisy | 1 | 2019 | 53 | 0.040 |
Why?
|
Alleles | 1 | 2011 | 6933 | 0.040 |
Why?
|
Insulin | 2 | 2016 | 6580 | 0.040 |
Why?
|
Databases, Factual | 3 | 2020 | 7729 | 0.040 |
Why?
|
Longitudinal Studies | 2 | 2020 | 13989 | 0.040 |
Why?
|
Toes | 2 | 2010 | 206 | 0.040 |
Why?
|
Clinical Coding | 1 | 2019 | 171 | 0.040 |
Why?
|
Europe | 2 | 2016 | 3339 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2020 | 340 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 199 | 0.040 |
Why?
|
Osteonecrosis | 1 | 2019 | 227 | 0.040 |
Why?
|
Delphi Technique | 1 | 2021 | 778 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2019 | 240 | 0.040 |
Why?
|
Preoperative Care | 1 | 2007 | 2250 | 0.040 |
Why?
|
Hospital Mortality | 2 | 2021 | 5317 | 0.040 |
Why?
|
Limit of Detection | 1 | 2018 | 265 | 0.040 |
Why?
|
Hospital Information Systems | 1 | 2019 | 395 | 0.040 |
Why?
|
Liver Neoplasms | 2 | 2010 | 4253 | 0.040 |
Why?
|
Research Design | 1 | 2013 | 5987 | 0.040 |
Why?
|
Injections, Subcutaneous | 1 | 2018 | 666 | 0.040 |
Why?
|
Logistic Models | 3 | 2021 | 13408 | 0.040 |
Why?
|
Depression | 1 | 2016 | 7766 | 0.040 |
Why?
|
Pleural Effusion | 1 | 2019 | 338 | 0.040 |
Why?
|
Lupus Nephritis | 1 | 2019 | 310 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14722 | 0.030 |
Why?
|
Treatment Failure | 1 | 2021 | 2618 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23403 | 0.030 |
Why?
|
Fatal Outcome | 2 | 2010 | 1850 | 0.030 |
Why?
|
Endpoint Determination | 1 | 2018 | 601 | 0.030 |
Why?
|
Critical Pathways | 1 | 2018 | 476 | 0.030 |
Why?
|
Indians, North American | 1 | 2018 | 355 | 0.030 |
Why?
|
Reference Standards | 1 | 2018 | 1025 | 0.030 |
Why?
|
Age Distribution | 1 | 2020 | 2902 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1125 | 0.030 |
Why?
|
Athletes | 1 | 2021 | 1093 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1170 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2017 | 13102 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2018 | 2971 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2018 | 2886 | 0.030 |
Why?
|
Outpatients | 1 | 2019 | 1486 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2021 | 2569 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1209 | 0.020 |
Why?
|
Peptides | 1 | 2022 | 4409 | 0.020 |
Why?
|
Japan | 1 | 2014 | 1360 | 0.020 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 57 | 0.020 |
Why?
|
United Arab Emirates | 1 | 2009 | 42 | 0.020 |
Why?
|
Cryoglobulinemia | 1 | 2009 | 87 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2019 | 1637 | 0.020 |
Why?
|
Poverty | 1 | 2020 | 2660 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2670 | 0.020 |
Why?
|
Infarction | 1 | 2010 | 244 | 0.020 |
Why?
|
Educational Status | 1 | 2016 | 2540 | 0.020 |
Why?
|
Hemianopsia | 1 | 2009 | 122 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10252 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2018 | 2716 | 0.020 |
Why?
|
Antiphospholipid Syndrome | 1 | 2009 | 173 | 0.020 |
Why?
|
Regression Analysis | 1 | 2017 | 6459 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 357 | 0.020 |
Why?
|
Fingers | 1 | 2010 | 513 | 0.020 |
Why?
|
Neoplasms | 1 | 2015 | 21683 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2009 | 1588 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12788 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2014 | 4740 | 0.020 |
Why?
|
Beverages | 1 | 2010 | 820 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12959 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 2421 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
Glucuronidase | 1 | 2005 | 207 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6895 | 0.010 |
Why?
|
Platelet Count | 1 | 2006 | 781 | 0.010 |
Why?
|
Reference Values | 1 | 2011 | 4982 | 0.010 |
Why?
|
Echocardiography, Transesophageal | 1 | 2010 | 1133 | 0.010 |
Why?
|
Sepsis | 1 | 2017 | 2593 | 0.010 |
Why?
|
Pilot Projects | 1 | 2016 | 8324 | 0.010 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1873 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1364 | 0.010 |
Why?
|
Vision Disorders | 1 | 2010 | 1058 | 0.010 |
Why?
|
Stroke Volume | 1 | 2014 | 5007 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
Ischemia | 1 | 2010 | 1907 | 0.010 |
Why?
|
Data Collection | 1 | 2010 | 3341 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2016 | 57776 | 0.010 |
Why?
|
Syndrome | 1 | 2005 | 3251 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2011 | 2071 | 0.010 |
Why?
|
Weight Loss | 1 | 2010 | 2622 | 0.010 |
Why?
|
Health Personnel | 1 | 2011 | 3218 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 25043 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7474 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12208 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2009 | 7181 | 0.010 |
Why?
|
Genotype | 1 | 2005 | 12951 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2005 | 7880 | 0.010 |
Why?
|
Obesity | 1 | 2007 | 12745 | 0.000 |
Why?
|
Brain | 1 | 2010 | 26385 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2010 | 35421 | 0.000 |
Why?
|